Person:
Flores, Juan Carlos

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Flores

First Name

Juan Carlos

Name

Flores, Juan Carlos

Filters

20221

Settings

Author's Publications: search.filters.isAuthorOfPublication.ca8b8af3-8427-4721-9585-077159f922df

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Publication
    Effectiveness of CoronaVac Among Children 3 to 5 During the Omicron SARS-CoV-2 Outbreak
    (Research Square Platform LLC, 2022-05-23) Jara, Alejandro; Undurraga Fourcade, Eduardo Andres; Zubizarreta, Jose R.; Gonzalez, Cecilia; Acevedo, Johanna; Pizarro, Alejandra; Vergara, Veronica; Soto-Marchant, Mario; Gilabert, Rosario; Flores, Juan Carlos; Suarez, Pamela; Leighton, Paulina; Eguiguren, Pablo; Rios, Juan Carlos; Fernandez, Jorge; Garcia-Escorza, Heriberto; Araos Bralic, Rafael
    Abstract The outbreak of the B.1.1.529 lineage of SARS-CoV-2 (omicron) has caused an unprecedented number of Covid-19 cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but the evidence is sparse or non-existing. Leveraging a population-based cohort of 490,694 children aged 3–5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of CoronaVac using inverse probability-weighted survival regression models to estimate hazard ratios of complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between December 6, 2021, and February 26, 2022, during the omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95%CI, 36.5–39.9) against Covid-19, 64.6% (95%CI, 49.6–75.2) against hospitalization, and 69.0% (95%CI, 18.6–88.2) to prevent intensive care unit admission. The effectiveness was modest; however, protection against severe disease remained high.